Abeona Therapeutics
ABEO
52 hedge funds and large institutions have $13.7M invested in Abeona Therapeutics in 2021 Q4 according to their latest regulatory filings, with 12 funds opening new positions, 11 increasing their positions, 12 reducing their positions, and 18 closing their positions.
0.12% more ownership
Funds ownership: 1% → 1.12% (+0.12%)
8% less repeat investments, than reductions
Existing positions increased: 11 | Existing positions reduced: 12
10% less funds holding
Funds holding: 58 → 52 (-6)
33% less first-time investments, than exits
New positions opened: 12 | Existing positions closed: 18
52% less capital invested
Capital invested by funds: $28.3M → $13.7M (-$14.6M)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Point72 Asset Management
Stamford,
Connecticut
|
+$2.35M |
| 2 |
Assenagon Asset Management
Senningerberg,
Luxembourg
|
+$2.06M |
| 3 |
D.E. Shaw & Co
New York
|
+$1.85M |
| 4 |
Renaissance Technologies
New York
|
+$1.56M |
| 5 |
Morgan Stanley
New York
|
+$1.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NAM
Nexpoint Asset Management
Dallas,
Texas
|
-$648K |
| 2 |
KCM
Knoll Capital Management
Miami,
Florida
|
-$473K |
| 3 |
JP Morgan Chase
New York
|
-$400K |
| 4 |
ACM
ACT Capital Management
Wayne,
Pennsylvania
|
-$311K |
| 5 |
HF
HRT Financial
New York
|
-$215K |
ABEO Hedge Fund Activity: Q4 2021 in Review
52 of the 6,498 institutional investors tracked by Wall St. Rank reported a position in Abeona Therapeutics (ABEO) for Q4 2021, worth a combined $13.7M — down 52% from $28.3M a quarter earlier.
Sellers outnumbered buyers: 18 funds closed out of ABEO and 12 opened new positions — a net loss of 6 holders — while 12 trimmed existing stakes and 11 added.
The largest buyer was Point72 Asset Management, opening a new position worth an estimated $2.35M. The largest seller was Nexpoint Asset Management, exiting entirely with an estimated $648K sold.
- 52 institutional investors held Abeona Therapeutics (ABEO) as of Q4 2021, down from 58 in Q3 2021.
- Funds reported $13.7M of Abeona Therapeutics stock for Q4 2021, down 52% quarter-over-quarter.
- 12 funds opened new Abeona Therapeutics positions in Q4 2021 and 18 closed out, a net change of -6 holders.
- The largest Abeona Therapeutics buyer in Q4 2021 was Point72 Asset Management, an estimated $2.35M added.
- The largest Abeona Therapeutics seller in Q4 2021 was Nexpoint Asset Management, an estimated $648K sold.
Based on aggregated 13F filings for Q4 2021.